SA PRO
Free Account
Verrica Pharmaceuticals Inc.VRCANASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating
Buy
9 analysts·Limited coverage
67%
Rating Distribution
Strong Buy
00%
Buy
667%
Hold
333%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 128% higher.

Bear Case
$17.00
+128%
Consensus
$17.00
+128%
Bull Case
$17.00
+128%
Price Range9 analysts
Low
Consensus
High
$17.00
$17.00
Current Target
Current Price
$7.45
Upside to Target
$9.55

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 18, 2025Loop Capital Markets
Brookline Capital Markets Upgrades Verrica Pharmaceuticals (VRCA) to Buy
Target:$17.00
+111.2%from $8.05
May 14, 2024Jefferies
Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies
Target:$12.00
+6.4%from $11.28
May 14, 2024H.C. Wainwright
Verrica Pharmaceuticals (VRCA) PT Raised to $14 at H.C. Wainwright
Target:$14.00
+46.4%from $9.56
Jul 25, 2023Needham
Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval
Target:$10.00
+88.0%from $5.32

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance